NCT05541822 2025-05-22To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET DysregulationAbion IncPhase 2 Recruiting178 enrolled